Drug for Fatty Liver Works in Trial

Thursday, 09 Jan 2014 12:16 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Intercept Pharmaceuticals Inc said an analysis by an independent safety committee showed that its liver disease drug met the main goal of a mid-stage trial, sending the company's shares soaring.
Intercept shares more than doubled to $169 in premarket trading on Thursday.
The company said it had stopped the trial after the committee found that the drug, obeticholic acid, showed statistically significant improvement in patients, compared with a placebo.
Nasdaq-listed Intercept said the committee made the recommendation after reviewing liver biopsy data from about half of the 283 patients enrolled in the trial.
The trial tested the drug in patients with non-alcoholic steatohepatitis, a form of liver inflammation caused by a build-up of fat.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved